Home/Pipeline/USP30 Inhibitor Program

USP30 Inhibitor Program

Parkinson's Disease

PreclinicalActive

Key Facts

Indication
Parkinson's Disease
Phase
Preclinical
Status
Active
Company

About Vincere Biosciences

Vincere Biosciences is a preclinical-stage biotech targeting age-related diseases through the modulation of mitophagy, the cellular process for removing damaged mitochondria. The company has identified USP30 inhibition as its lead mechanism and is advancing a pipeline of small molecules, with the first candidate expected to enter human trials within 12 months. Backed by over $8 million in non-dilutive grant funding and a syndicate of expert investors, Vincere leverages a seasoned, virtual-team model and a strong scientific advisory board to de-risk its drug discovery programs.

View full company profile

About Vincere Biosciences

Vincere Biosciences is a preclinical-stage biotech targeting age-related diseases through the modulation of mitophagy, the cellular process for removing damaged mitochondria. The company has identified USP30 inhibition as its lead mechanism and is advancing a pipeline of small molecules, with the first candidate expected to enter human trials within 12 months. Backed by over $8 million in non-dilutive grant funding and a syndicate of expert investors, Vincere leverages a seasoned, virtual-team model and a strong scientific advisory board to de-risk its drug discovery programs.

View full company profile

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
NUZ-001Neurizon TherapeuticsPreclinical
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease Portfolio (Platform-derived)WD PharmaceuticalNot Disclosed (Likely Preclinical/Early Clinical)
UX-DA001UniXellPhase 1
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical